Announcements Trials
Browse Landscape

Phase

Phase NA 16Phase 2 3Phase EARLY_PHASE1 1Phase 3 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 187Neoplasm Metastasis 150Neoplasms 141Leukemia, Myeloid, Acute 138Colorectal Neoplasms 131Breast Neoplasms 120Melanoma 95Ovarian Neoplasms 93Prostatic Neoplasms 89Recurrence 85Multiple Myeloma 83Lung Neoplasms 78Pancreatic Neoplasms 77Glioblastoma 77Squamous Cell Carcinoma of Head and Neck 75Myelodysplastic Syndromes 66Lymphoma, Non-Hodgkin 65Triple Negative Breast Neoplasms 57Glioma 57Stomach Neoplasms 54Endometrial Neoplasms 51Precursor Cell Lymphoblastic Leukemia-Lymphoma 50Carcinoma, Renal Cell 49Brain Neoplasms 48Small Cell Lung Carcinoma 47Lymphoma, Large B-Cell, Diffuse 45Carcinoma, Hepatocellular 45Lymphoma, B-Cell 42Lymphoma, Follicular 40Advanced Solid Tumors 40

Interventions

ruxolitinib 1Standard of Care 1Specimen Handling 1Practice Guidelines as Topic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hematopoietic and Lymphatic System Neoplasm × 90 days × Clear all
NCT07025538 2026-04-20

Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

City of Hope Medical Center

Phase 1 Recruiting
42 enrolled

Hematopoietic and Lymphatic System Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡